Status: Not yet recruiting
Vilamakitug in Spondyloarthritis Placebo-controlled Investigation for Efficacy
The goal of this clinical trial is to find out if the study drug will work as a new therapy for axSpA patients. This study is placebo-controlled, and evaluates if study drug can treat symptoms of axSpA, including global disease activity, pain, function and inflammation.
Participants needed: 150
Trial details
Phase: Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: XBiotech, Inc.Updated: May 14, 2026
Eligibility criteria
Male or female aged ≥18 and ≤65 years, with body weight >40 kg at screening, who... [+4]
History of treatment with vilamakitug [+5]